Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10967132 | 0.89 | PTGS2 (0.44) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL10965811 | 0.88 | CES2 (0.48) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL10967623 | 0.83 | ERCC5 (0.42) | — | |
| SCHEMBL7736497 | 0.81 | SIGMAR1 (0.47) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9092744 | 0.79 | SIGMAR1 (0.53) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8553233 | 0.78 | CES2 (0.42) | TBXAS1 | |
| SCHEMBL9481041 | 0.78 | MTNR1A (0.46) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4630812 | 0.77 | MTNR1A (0.48) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6158120 | 0.76 | KDM1A (0.41) | MTNR1AMTNR1BAKT1CYP1A2 | |
| SCHEMBL6158123 | 0.76 | KDM1A (0.41) | MTNR1AMTNR1BAKT1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1839657-A2 | A method for treating vascular headaches | THE GENERAL HOSPITAL CORPORATION (US) | 2007-10-03 | — | — | EP | claimed |
| EP-0789567-A4 | A METHOD FOR TREATING VASCULAR HEADACHES | GEN HOSPITAL CORP (US) | 1999-01-13 | — | — | EP | claimed |
| EP-0789567-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1997-08-20 | — | — | EP | claimed |
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | claimed |
| WO-1996015782-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| EP-1839657-A2 | A method for treating vascular headaches | THE GENERAL HOSPITAL CORPORATION (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20040266802-A1 | Tricyclic analgesics | CALVET ALAIN (US) | 2004-12-30 | — | — | US | disclosed |
| US-20030143729-A1 | DNA encoding taurine and GABA transporters and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-07-31 | — | — | US | disclosed |
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6407096-B1 | 1,4-BENZOTHIAZINE AND 1,4-BENZOXAZINE DERIVATIVES; HYPOTENSIVE, ANTIISCHEMIC, ANTIALLERGEN, ANTIASTHMATIC AND ANTICOAGULANT AGENTS; CARDIOVASCULAR DISORDERS | TORAY INDUSTRIES, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| US-6323235-B1 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS AND ENZYME INHIBITORS | OHTAKE ATSUSHI (JP) | 2001-11-27 | — | — | US | disclosed |
| US-6225115-B1 | DNA encoding taurine and GABA transporters and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-5766848-A | RECEPTOR BINDING ASSAY TO DETECT COMPOUND BOUND TO BETAINE/G-AMINOBUTYRIC ACID TRANSPORTER EXPRESSED ON SURFACE OF NONNEURONAL CELLS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-5767117-A | BINDING OF AN AGONIST TO A 4-AMINOBUTYRIC ACID RECEPTOR AT THE BENZODIAZEPINE SITE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0789567-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0751126-A1 | BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME | TORAY INDUSTRIES, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996015782-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996004790-A1 | DNA ENCODING A HUMAN BETAINE/GABA TRANSPORTER AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-22 | — | — | WO | disclosed |
| EP-0102034-A1 | Spiro(2H-1,4-benzodioxepin-3(5H)4'-piperidine and 3'-pyrrolidino) compounds, a process for preparing the same and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1984-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266802-A1 | Tricyclic analgesics | OPRM1, OPRL1, OPRD1 | MTNR1A 221/4885MTNR1B 205/4885CHRNB2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.